Free Trial
NASDAQ:SEEL

Seelos Therapeutics 8/14/2024 Earnings Report

Seelos Therapeutics EPS Results

Actual EPS
$1.92
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Seelos Therapeutics Revenue Results

Actual Revenue
$0.38 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Seelos Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Seelos Therapeutics' next earnings date is estimated for Monday, May 12, 2025, based on past reporting schedules.

Conference Call Resources

Seelos Therapeutics Earnings Headlines

Seelos Therapeutics, Inc. (SEELQ)
Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
Seelos Therapeutics Inc SEELQ
See More Seelos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Seelos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Seelos Therapeutics and other key companies, straight to your email.

About Seelos Therapeutics

Seelos Therapeutics (NASDAQ:SEEL), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.

View Seelos Therapeutics Profile

More Earnings Resources from MarketBeat